2027 Innovations in Regulatory Science Summit

About This Event

The 8th annual 2027 Innovations in Regulatory Science Summit will highlight the latest developments in regulatory science, with panels on manufacturing and supply chain of medical products, artificial intelligence, FDA leadership, and the role of regulatory science from challenges to solutions. Debates on exciting topics in regulatory science will also be featured. The goal of the Summit is to stimulate discussion across sectors and to critically consider lessons learned and scientific issues that need addressing to expeditiously and safely advance the development, approval, and monitoring of medical products.

The Summit will be held as a hybrid event at Robertson Auditorium at the Mission Bay Conference Center at UCSF, 1675 Owens St., San Francisco, CA. In-person and virtual attendance options are available.

UCSF welcomes all participants. If you need a reasonable accommodation to participate in this event because of a disability, please contact [email protected] as soon as possible.

Schedule

Times shown in Pacific Time.

TimeTopicPresenter(s)
8:30 AMBreakfast & Sign-In / Networking 
9:00 AMWelcome
  • Kathy Giacomini, PhD, BSPharm, Dean, School of Pharmacy, UCSF
  • Kuldev Singh, MD, MPH, Professor of Opthamology, Stanford University
9:05 AMOpening Remarks
  • Sam Hawgood, MBBS, Chancellor, UCSF
  • Lloyd Minor, MD, Dean, Stanford University School of Medicine
9:15 AMInnovative Research in Regulatory ScienceKathy Giacomini, PhD, BSPharm, Dean, School of Pharmacy, 
9:25 AMTBDSpeaker to be confirmed
9:45 AMPanel 1: AI and Data Science to Support Regulatory Intelligence

Moderator: Russ Altman, MD, PhD, Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science, Stanford University

Panelists: 

  • Tala H. Fakhouri, PhD, MPH, Chief AI & Regulatory Strategy Officer, Parexel
  • Robert Lionberger, PhD, Director, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research (CDER), US FDA
  • Robert M. Wachter, MD, Professor and Chair, Department of Medicine, UCSF
10:35 AM Break / Networking 
10:55 AMDebate 1: TBD 
11:15 AMPanel 2: US FDA Center Directors Forum

Moderators: 

  • Kuldev Singh, MD, MPH, Professor of Opthamology, Stanford University
  • Invited: Steve Kozlowski, MD, Chief Scientific Officer, US FDA

Panelists: 

  • Michael, Davis, MD, PhD, Director, Center for Drug Evaluation and Research, US FDA
  • Karim Mikhail, MSc, BPharm, Director, Center for Biologics Evaluation and Research, US FDA
  • Michelle Tarver, MD, PhD, Director, Center for Devices and Radiological Health, US FDA
12:15 PMLunch / Poster Session / Networking 
1:05 PMPanel 3: Harnessing Regulatory Science to Navigate Challenges and Drive Best Practices

Moderators: 

  • Kathy Giacomini, PhD, BSPharm, Dean, School of Pharmacy, UCSF; 
  • Michelle Rohrer, PhD, Former Senior Vice President, Global Head of Product Development Regulatory, Roche

Panelists: 

  • Kevin Bugin, MS, PhD, Head of Global Regulatory Policy and Intelligence, Amgen
  • Sean Curtis, MD, SVP, Global Regulatory Affairs and Clinical Safety, Merck
  • Carlos O. Garner, PhD, Senior Vice President, Global Regulatory Affairs and Head, Lilly Regenerative Medicines, Eli Lilly and Company
  • Nahid Latif, Chief Regulatory Officer, Head of Global Regulatory Affairs, Takeda
1:45 PMDebate 2: Is It Too Late for the United States to Invest in Onshore Drug Manufacturing?

Moderator: Laura Esserman, MD, MBA, Professor of Surgery and Radiology, UCSF

Debaters: 

  • Pro: Andrew W. Lo, PhD, Charles E. and Susan T. Harris Professor, Sloan School of Management and Director, Laboratory for Financial Engineering, Massachusetts Institute of Technology
  • Con: Hesham A. Abdullah, MD MSc, Senior Vice President, Global Head, Oncology, Research & Development, GSK 
2:05 PMPanel 4: Disruption in Drug Supply and Development in the US: Can Innovation and Onshore Manufacturing Be the Solution? 

Moderator: Laura Esserman, MD, MBA, Professor of Surgery and Radiology, UCSF

Panelists: 

  • B. Frank Gupton, PhD, Floyd D. Gottwald Chair of Pharmaceutical Engineering and Department Chair, Chemical and Biomolecular Engineering, Virginia Commonwealth University
  • Dan Hartman, MD, Director, Integrated Development, Gates Foundation
  • Kevin Schulman, MD, Professor of Medicine, Stanford University
3:05 PMBreak / Networking 
3:20 PMPanel 5: FDA Chiefs Chat

Moderator: Andy Plump, MD, PhD, President, Research and Development, Takeda Pharmaceutical

Panelists: 

  • Robert Califf, MD, Adjunct Professor of Medicine, Cardiology, Duke University
  • Scott Gottlieb, MD, Partner, New Enterprise Associates
  • Mark McClellan, MD PhD, Director of the Duke-Margolis Institute for Health Policy, Duke University 
  • Norman Sharpless, MD, Professor of Cancer Policy and Innovation at UNC School of Medicine and Managing Director of Hatteras Discovery Fund
4:20 PMClosing Remarks 
4:30 PMIntroduction to Networking Reception 
4:40 PMPoster Reception / Networking Reception 

2027 Summit Planning Committee

Planning Committee